Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration.

Amine Oxidase (Copper-Containing) / metabolism Anaphylaxis Benzamidines Diminazene Edetic Acid Guanidines / adverse effects Histamine / adverse effects Humans

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
08 2022
Historique:
received: 01 04 2022
accepted: 16 05 2022
pubmed: 11 6 2022
medline: 22 7 2022
entrez: 10 6 2022
Statut: ppublish

Résumé

Nafamostat is an approved short-acting serine protease inhibitor. However, its administration is also associated with anaphylactic reactions. One mechanism to augment hypersensitivity reactions could be inhibition of diamine oxidase (DAO). The chemical structure of nafamostat is related to the potent DAO inhibitors pentamidine and diminazene. Therefore, we tested whether nafamostat is a human DAO inhibitor. Using different activity assays, nafamostat reversibly inhibited recombinant human DAO with an IC

Identifiants

DOI: 10.1124/jpet.122.001248 PMID: 35688477
pubmed: 35688477
pii: jpet.122.001248
doi: 10.1124/jpet.122.001248
doi:

Substances chimiques

Benzamidines 0
Guanidines 0
Histamine 820484N8I3
Edetic Acid 9G34HU7RV0
Amine Oxidase (Copper-Containing) EC 1.4.3.21
nafamostat Y25LQ0H97D
Diminazene Y5G36EEA5Z

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-122

Informations de copyright

Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Thomas Boehm (T)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.) thomas.boehm@meduniwien.ac.at.
ORCID: 0000-0002-8294-0797

Marion Alix (M)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Karin Petroczi (K)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Serhii Vakal (S)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Elisabeth Gludovacz (E)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Nicole Borth (N)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Tiina A Salminen (TA)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Bernd Jilma (B)

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (T.B., K.P., E.G., B.J.); Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering (M.A., S.V., T.A.S.), and InFLAMES Research Flagship Center (M.A., S.V., T.A.S.), Åbo Akademi University, Turku, Finland; and Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria (E.G., N.B.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on CH-NH2 group donors › Amine oxidase (copper-containing) › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Anaphylaxie › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Composés chimiques organiques › Amidines › Benzamidines › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Composés chimiques organiques › Triazènes › Diminazène › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acide édétique › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Composés chimiques organiques › Amidines › Guanidines › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Histamine › Nafamostat is a Potent Human Diamine Oxidase...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nafamostat is a Potent Human Diamine Oxidase...